novavax vaccine - Search News

Order byBest matchMost fresh

FDA plans to limit COVID vaccine to only high-risk people

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who hav...

· 6d · on MSN

FDA approves Novavax's COVID-19 vaccine with limitations

· 6d · on MSN

FDA approves Novavax COVID vaccine with new conditions

· 1d

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot

Expert advisors for the Food and Drug Administration met Thursday to discuss which virus strain this year's updated COVID-19 vaccines should target.

Arizona PBS · 1d

FDA ends routine COVID shots for healthy young Americans

STAT · 1d

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

F.D.A. Approves Novavax Covid Vaccine With Stricter New Conditions

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

STAT6d

Novavax wins narrowed approval for its Covid-19 shot after delay

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

BioPharma Dive5d

Novavax’s COVID vaccine gets FDA approval, but with limits

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

6don MSN

New Covid Vaccine Approved - But Not For Everyone

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the letter said.

5don MSN

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot.

New Trump vaccine policy might limit access to your future COVID shots: 10 points

The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for healthy individuals under 65. This decision contrasts with previous recommendations for annual shots for all.

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,